Mereo BioPharma Group plc Publication of Annual Report (3962J)
April 03 2018 - 1:01AM
UK Regulatory
TIDMMPH
RNS Number : 3962J
Mereo BioPharma Group plc
03 April 2018
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Mereo BioPharma publishes its Annual Report for the Year Ended
December 31, 2017
London, April 3, 2018 - Mereo BioPharma Group plc (AIM: MPH), a
multi-asset biopharmaceutical company focused on the acquisition,
development and commercialisation of innovative therapeutics that
aim to improve outcomes for patients with rare and specialty
diseases, today confirms that its Annual Report and Accounts for
the year ended December 31, 2017 has been published on the Company
website at www.mereobiopharma.com and will shortly be posted to
those shareholders who have not elected to receive electronic
communication.
The Annual General Meeting will be held on June 21, 2018 at
11.30am at the offices of Latham & Watkins LLP, 99 Bishopsgate,
London EC2M 3XF. Notice of the meeting and related documents will
be posted to shareholders in due course.
For Further Enquiries:
+44 (0)333 023
Mereo BioPharma Group plc 7319
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial
Officer
Nominated Adviser and Joint Broker +44 (0)20 7894
Cantor Fitzgerald Europe 7000
Phil Davies
Will Goode
Joint Broker +44 (0)20 7653
RBC Capital Markets 4000
Rupert Walford
Laura White
UK Public Relations Advisor to
Mereo Biopharma +44 (0)20 3727
FTI Consulting 1000
Ben Atwell
Simon Conway
Brett Pollard
US Public Relations Advisor to
Mereo Biopharma +01 (0) 212
Burns McClellan 213 0006
Lisa Burns
Steven Klass
About Mereo
Mereo is a multi-asset biopharmaceutical company focused on the
acquisition, development and commercialization of innovative
therapeutics that aim to improve outcomes for patients with rare
and specialty diseases. The portfolio consists of four
clinical-stage product candidates, each of which were acquired from
large pharmaceutical companies: BPS-804 for the treatment of
osteogenesis imperfecta; AZD-9668 for the treatment of severe
alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute
exacerbations of chronic obstructive pulmonary disease, or AECOPD;
and BGS-649 for the treatment of hypogonadotropic hypogonadism
("HH") in obese men. Each of the Company's product candidates has
generated positive clinical data for Mereo's target indication or
in a related indication. The Company's strategy is to selectively
acquire product candidates that have already received significant
investment from pharmaceutical companies and that have substantial
preclinical, clinical and manufacturing data packages. Since
inception the Company has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for three of the product
candidates and announced positive top-line results from its Phase 2
clinical trial of BCT-197 as an acute therapy for patients with
AECOPD in December 2017 and positive top-line data from its Phase
2b dose-ranging study with BGS-649 for the treatment of HH. The
Company intends to commence additional late-stage clinical trials
in 2018.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DOCZMGZFLLFGRZG
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024